NEWS
Women As One and BridgeBio Join Forces to Tackle Gender Disparities in Cardiology
Published Date – 28 June 2024
Women As One is pleased to announce its 2024 Principal Corporate Membership with BridgeBio, marking a significant milestone in advancing diversity, equity, and inclusion in the medical field. This strategic partnership underscores BridgeBio’s increasing support for Women As One’s mission while recognizing BridgeBio as a steadfast advocate for diversity and innovation.
Founded to expand and promote the global talent pool in medicine, Women As One focuses on providing unique professional opportunities to women physicians, initially concentrating on cardiology. The organization develops programs that amplify, fortify, and unite global efforts towards gender equity in medicine.
In a proactive move to enhance its impact, Women As One sought out key organizations for partnership opportunities. BridgeBio emerged as an ideal collaborator due to its dedication to improving gender diversity and its mission to discover, create, test, and deliver transformative medicines for patients with genetic diseases.
“We are thrilled to embark on this groundbreaking partnership with BridgeBio,” said Roxana Mehran, MD, co-founder of Women As One. “Together, we aim to pioneer an innovative membership model that champions women physicians and fosters collective efforts to level the playing field in cardiology.”
The partnership entails several collaborative initiatives, including:
- Sponsorship of the 2024 Women As One Escalator Awards
- Elite sponsorship of the upcoming RISE @ ESC Congress 2024, in partnership with the European Society of Cardiology, scheduled for August 29th in London
- Elite sponsorship of Women As One’s 2024 Corporate Membership
- Exclusive sponsored reception at the American Heart Association conference in Chicago, Illinois, from November 16th to 19th
“We are excited to join forces with Women As One to drive positive change in the medical community,” said Julie Miller Everett, chief business officer of Eidos Therapeutics, the BridgeBio affiliate company developing acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM). “This partnership exemplifies our shared commitment to advancing diversity and innovation in medicine.”
Women As One extends a warm welcome to BridgeBio and looks forward to sharing updates on their collaborative progress throughout the year.